Notice of Issuance of a Provisional Disposition Order on Patent Infringement against a Generic of “Teribone™ Injection”
September 5, 2023
Asahi Kasei Pharma Corp.
On September 4, 2023, the Osaka District Court issued a provisional disposition order prohibiting Sawai Pharmaceutical Co., Ltd. (hereinafter “Sawai”) from manufacturing, marketing, and offering for sale “Teriparatide for Subcutaneous Injection 56.5 μg [SAWAI]” (a generic of “Teribone™ Injection” for osteoporosis; hereinafter “Sawai Product”).
Asahi Kasei Pharma Corp. (Head Office: Chiyoda-ku, Tokyo; President: Yoshikazu Aoki; hereinafter “Asahi Kasei Pharma”) filed the action for infringement of its patent right (Patent No. 6025881; FREEZE-DRIED PREPARATION CONTAINING HIGH-PURITY PTH AND METHOD FOR PRODUCING SAME) relating to “Teribone™ Injection” and sought injunction preventing Sawai from manufacturing and selling Sawai Product.
Under the provisional disposition order, Sawai is prohibited from manufacturing and selling Sawai Product manufactured using the patented manufacturing method for the duration of the patent right.
In addition, Asahi Kasei Pharma has sufficient supply capability to provide “Teribone™ Injection” to patients who need it.
Asahi Kasei Pharma values intellectual property rights as important management resources, and will continue to protect its intellectual property through resolute action against infringement of its intellectual property rights.